Sort
8,912 grants matching “sars cov 2”
SUBPOPULATIONS AND INTERMEDIATE OUTCOMES IN COPD (SPIROMICS) III - TASK AREA A
$6,734,645Erica Anderson · · N01 · FY2024 · HL
The Center for Innovation in Point-of-Care Technologies for HIV/AIDS atNorthwestern University (C-THAN) Supplemental Request
$6,707,769Robert L. Murphy · Northwestern University · U54 · FY2020 · EB
Antiviral Efficacy and Resistance Core
$6,599,276John Damon Chodera · Sloan-Kettering Inst Can Research · U19 · FY2022 · AI
1/2 REPRIEVE Extension for Trial Completion
$6,567,877Steven Kyle Grinspoon · Massachusetts General Hospital · UG3 · FY2023 · HL
CoVPN 3002 A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222 for the Prevention of COVID-19 LAB
$6,554,653Margaret Juliana McElrath · Fred Hutchinson Cancer Research Center · UM1 · FY2020 · AI
Viral Hemorrhagic Fevers: Disease Modeling and Transmission
$6,531,361Heinrich Feldmann · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
CEIRS - SARS-CoV-2 RESEARCH
$6,477,471Adolfo Garcia-Sastre · Icahn School Of Medicine At Mount Sinai · N01 · FY2020 · AI
COVID SARS-CoV-2 Assessment Viral Evolution (SAVE) VARIANT TESTING
$6,477,336Saliba Katy · Leidos Biomedical Research, Inc. · N01 · FY2021 · AI
Broad neutralization of pandemic threat coronaviruses
$6,423,268Paul D Bieniasz · Rockefeller University · P01 · FY2022 · AI
Task V12: Clinical Sample Testing for SARS-CoV-2 Vaccine Candidates
$6,398,512Thomas Rudge · Battelle Centers/Pub Hlth Res & Evaluatn · N01 · FY2020 · AI
CEIRR: SARS-CoV-2 Research Activities
$6,394,770Adolfo Garcia-Sastre · Icahn School Of Medicine At Mount Sinai · N01 · FY2022 · AI
Program in Clinical Research, Clinical Support Services and Clinical Training
$6,317,338Janet Hall · National Institute Of Environmental Health Sciences · ZID · FY2022 · ES
Optimizing nucleoside analog efficacy with novel exonuclease inhibitors
$6,271,219Craig E. Cameron · Stanford University · U19 · FY2022 · AI
The Michigan Infectious Disease Genomics (MIDGE) Center
$6,233,451Adam Lauring · University Of Michigan At Ann Arbor · U19 · FY2024 · AI
COVID-19 TARGETING DNA DAMAGE REPAIR PATHWAYS TO REDUCE SARS-COV-2 REPLICATION IN THE AIRWAYS
$6,198,263University Of California, Los Angeles · · FY2021 · Defense Health Agency
Stem Cell Translation Laboratory (SCTL)
$6,181,152Ilyas Singec · National Center For Advancing Translational Sciences · ZIA · FY2022 · TR
Task V11: General Safety Toxicity Testing, SARS-CoV-2
$6,134,108Thomas Rudge · Battelle Centers/Pub Hlth Res & Evaluatn · N01 · FY2024 · AI
REVERSE-Long COVID: A Multicenter Randomized, Placebo-Controlled Clinical Trial of Immunomodulation (with Baricitinib) for Long COVID Related ADRD
$6,107,805E Wesley Ely · Vanderbilt University Medical Center · R01 · FY2025 · AG
Scripps Clinical and Translational Science Hub
$6,029,792Eric Jeffrey Topol · Scripps Research Institute, The · UM1 · FY2023 · TR
Scripps Clinical and Translational Science Hub
$6,005,620Eric Jeffrey Topol · Scripps Research Institute, The · UM1 · FY2024 · TR
CODA: COvid and Diabetes Assessment
$5,999,551Russell L. Rothman · Vanderbilt University Medical Center · U01 · FY2023 · DK
Neuropathogenesis of Retroviral Infections
$5,993,146Avindra Nath · National Institute Of Neurological Disorders And Stroke · ZIA · FY2022 · NS
RADx-Rad Discoveries & Data: Consortium Coordination Center Program Organization
$5,954,423Lucila Ohno-Machado · University Of California, San Diego · U24 · FY2021 · LM
Vaccine and Treatment Evaluation Units (VTEU)
$5,921,655Hana M El Sahli · Baylor College Of Medicine · UM1 · FY2020 · AI
RADx-Rad Discoveries & Data: Consortium Coordination Center Program Organization
$5,853,027Lucila Ohno-Machado · Yale University · U24 · FY2023 · LM